Versant Venture Capital entities recently sold shares of LENZ Therapeutics, Inc. for a total of $10.1 million, with share prices ranging from $29.95 to $30.35.

On June 18, 2025, Versant Venture Capital VII, L.P. sold 100,000 shares at $29.95, followed by a sale of 100,877 shares at $30.35 on June 20, 2025.

Additionally, on the same day as the recent sales, Versant Venture Capital VI, L.P. sold 133,924 shares at $30.25, while still retaining a significant stake in LENZ.

Currently, Versant Venture Capital VII, L.P. holds 1,047,912 shares indirectly, Versant Venture Capital VI, L.P. holds 1,967,275 shares directly, and Versant Vantage II, L.P. holds 842,162 shares indirectly.

LENZ Therapeutics is focused on advancing its presbyopia treatment, LNZ100, which has a PDUFA target date of August 8, 2025.

The company has also entered into an exclusive licensing agreement with Lotus Pharmaceutical for commercialization in the Republic of Korea and select Southeast Asian countries, with potential earnings of up to $125 million.

At a recent stockholder meeting, LENZ Therapeutics elected new directors and ratified Ernst & Young LLP as its independent auditor, indicating strategic efforts to enhance its market presence.

Citi analysts have reiterated a Buy rating on LENZ Therapeutics, setting a price target of $45, citing the potential FDA approval of LNZ100 as a significant milestone.

Despite reporting a net loss per share of $0.53 for the first quarter of 2025, LENZ Therapeutics maintains a robust cash position of $194.1 million.

The stock has seen a remarkable increase of over 65% in the past year, with its current trading price at $29.94, according to InvestingPro data.